UroGen Pharma Stock Forecast, Price & News

UroGen Pharma (NASDAQ:URGN) Frequently Asked Questions

Is UroGen Pharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma or view top-rated stocks.

How has UroGen Pharma's stock been impacted by Coronavirus?

UroGen Pharma's stock was trading at $23.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, URGN shares have decreased by 64.4% and is now trading at $8.49.
View which stocks have been most impacted by COVID-19.

When is UroGen Pharma's next earnings date?

UroGen Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for UroGen Pharma.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.26) by $0.09. The company earned $11.35 million during the quarter, compared to the consensus estimate of $15.90 million. UroGen Pharma had a negative net margin of 283.41% and a negative trailing twelve-month return on equity of 173.25%. During the same period last year, the company earned ($1.31) EPS.
View UroGen Pharma's earnings history.

What price target have analysts set for URGN?

1 analysts have issued 1 year target prices for UroGen Pharma's stock. Their forecasts range from $50.00 to $50.00. On average, they expect UroGen Pharma's share price to reach $50.00 in the next year. This suggests a possible upside of 488.9% from the stock's current price.
View analysts' price targets for UroGen Pharma or view top-rated stocks among Wall Street analysts.

Who are UroGen Pharma's key executives?

UroGen Pharma's management team includes the following people:

• Elizabeth Barrett, President, Chief Executive Officer & Director
• Molly Henderson, Chief Financial & Accounting Officer (LinkedIn Profile)
• Marina Konorty, EVP-Research & Development & Technical Operations
• Mark P. Schoenberg, Chief Medical Officer (LinkedIn Profile)
• Moran Mieron, Director-Research & Pre-Clinical Affairs

Who are some of UroGen Pharma's key competitors?

Some companies that are related to UroGen Pharma include 2seventy bio (TSVT), Abliva AB (publ) (NEVPF), Acusphere (ACUS), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), Akorn (AKRXQ), Alseres Pharmaceuticals (ALSE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), AXM Pharma (AXMP), Biostar Pharmaceuticals (BSPM) and Bright Minds Biosciences (DRUG).
View all of URGN's competitors.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu Biopharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How do I buy shares of UroGen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $8.49.

How many employees does UroGen Pharma have?

UroGen Pharma employs 187 workers across the globe.

What is UroGen Pharma's official website?

The official website for UroGen Pharma is www.urogen.com.

Where are UroGen Pharma's headquarters?

UroGen Pharma is headquartered at 400 Alexander Park, Princeton NJ, 08540.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at (646) 768-9780 or via email at [email protected].